Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
Journal of the American Academy of Dermatology|May 28, 2018
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 studyCraig Leonardi, Catherine Maari, Sandra Philipp, et al.American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.Journal of the American Academy of Dermatology|October 4, 2016
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasisSteven R Feldman, Diamant Thaçi, Melinda Gooderham, et al.Annals of the Rheumatic Diseases|May 10, 2017
Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage studyAlexander Egeberg, Lars Erik Kristensen, Jacob P Thyssen, et al.Journal of the American Academy of Dermatology|August 23, 2017
The relationship between duration of psoriasis, vascular inflammation, and cardiovascular eventsAlexander Egeberg, Lone Skov, Aditya A Joshi, et al.Journal of Drugs in Dermatology : JDD|February 21, 2018
Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical TrialsNeil H Shear, Carle Paul, Andrew Blauvelt, et al.Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.Journal of the American Academy of Dermatology|February 23, 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension studyKim A Papp, James G Krueger, Steven R Feldman, et al.Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.Pageof 7